Literature DB >> 15031599

Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.

Masaki Sugimura1, Satoru Sagae, Shin-Ichi Ishioka, Yoshihiro Nishioka, Kuniko Tsukada, Ryuichi Kudo.   

Abstract

BACKGROUND: To understand the complicated network of paclitaxel (PTX)-induced apoptosis pathways and to elucidate mechanisms of drug resistance in ovarian cancer, we looked at PTX-induced apoptosis by using cDNA microarray. We also quantitated the changes in apoptosis-related proteins in the process of apoptosis.
METHODS: An ovarian cancer cell line KF, and its PTX-resistant clone KFTX, were treated with PTX or carboplatin (CBDCA). After exposure to PTX or CBDCA, the induction of apoptosis was examined by internucleosomal DNA fragmentation. Changes in mRNA expression after 12 h of exposure to PTX were studied using cDNA microarray and RT-PCR. Changes in P53 and Bcl-2 levels were also measured over 24 h by ELISA.
RESULTS: With increased doses of PTX or CBDCA, an increase in apoptosis was noted in both cell lines. cDNA microarray revealed that PTX treatment upregulated expression of caspase 1, 2, 3, 4, 6, 9, 10, their activator apaf-1, and stress reaction-related genes, gadd34, gadd153 in KF, although most of them were unchanged or downregulated in KFTX. bag-1 and hsc70 were markedly upregulated in KFTX. p53 and bcl-2 were not upregulated in either cell line. Results from protein studies also supported the cDNA microarray data.
CONCLUSIONS: p53-independent mitochondrial pathways and stress-reaction-induced pathways play critical roles in PTX-induced apoptosis in ovarian cancer cells. Suppression of those pathways and upregulation of bag-1 and hsp-70 played an important role in acquiring resistance to PTX. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031599     DOI: 10.1159/000076335

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  11 in total

1.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics.

Authors:  James D Orth; Rainer H Kohler; Floris Foijer; Peter K Sorger; Ralph Weissleder; Timothy J Mitchison
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

2.  LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells.

Authors:  Ronggao Chen; Yiting Qiao; Wendi Hu; Qiyang Cheng; Haiyang Xie; Lin Zhou; Xiao Xu; Shusen Zheng; Donghai Jiang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

3.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.

Authors:  Marcus Bernardini; Chung-Hae Lee; Ben Beheshti; Mona Prasad; Monique Albert; Paula Marrano; Heather Begley; Patricia Shaw; Al Covens; Joan Murphy; Barry Rosen; Salomon Minkin; Jeremy A Squire; Pascale F Macgregor
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

4.  The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.

Authors:  Can Sarisozen; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2014-07-10       Impact factor: 5.571

5.  Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b.

Authors:  Regina Maushagen; Stefan Reers; Ann-Christin Pfannerstill; Angelina Hahlbrock; Roland Stauber; Ramtin Rahmanzadeh; Dirk Rades; Ralph Pries; Barbara Wollenberg
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-01       Impact factor: 4.553

6.  Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

Authors:  Shu-Fu Lin; Sizhi Paul Gao; Daniel L Price; Sen Li; Ting-Chao Chou; Paramjeet Singh; Yu-Yao Huang; Yuman Fong; Richard J Wong
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

7.  Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

8.  High-throughput, microscope-based sorting to dissect cellular heterogeneity.

Authors:  Nicholas Hasle; Anthony Cooke; Sanjay Srivatsan; Heather Huang; Jason J Stephany; Zachary Krieger; Dana Jackson; Weiliang Tang; Sriram Pendyala; Raymond J Monnat; Cole Trapnell; Emily M Hatch; Douglas M Fowler
Journal:  Mol Syst Biol       Date:  2020-06       Impact factor: 11.429

9.  Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Authors:  Khalid Abubaker; Rodney B Luwor; Hongjian Zhu; Orla McNally; Michael A Quinn; Christopher J Burns; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed
Journal:  BMC Cancer       Date:  2014-05-06       Impact factor: 4.430

10.  CIRCNV: Detection of CNVs Based on a Circular Profile of Read Depth from Sequencing Data.

Authors:  Hai-Yong Zhao; Qi Li; Ye Tian; Yue-Hui Chen; Haque A K Alvi; Xi-Guo Yuan
Journal:  Biology (Basel)       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.